Can someone clarify this for me - Revive Therapeutics Patent Portfolio and Product Pipeline - Bucillamine in the treatment of Infectious diseases, including COVID-19.
My question is - When we complete the phase 3 trials for Covid, does the drug then have to go through separate trials for its use in treating other infectious diseases i.e. flu, COVID 20, etc or what’s the deal?
Market Data 
Markets 
AI
